DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Mefenamic acid, 989
adverse effects and side effects of,
989
compared to aspirin, 968t
dosage and administration of, 968t
pharmacokinetics of, 968t
therapeutic uses of, 968t
Mefloquine, 1392t, 1408–1409
pharmacokinetics of, 1860t
MEFOXIN (cefoxitin), 1494t, 1496t
MEGACE (megestrol acetate), 1668t–
1670t, 1756
Megestrol acetate, 1668t–1670t, 1765
in cancer chemotherapy, 1756
structure of, 1761f
MEH. See Microsomal epoxide
hydrolase (mEH)
Meibomian glands, 1773
Meibomianitis, bacterial, treatment of,
1781t
Meissner’s plexus. See Submucosal
plexus
Melanocytes, 1804
α-Melanocyte-stimulating hormone
(α-MSH), 1106t
β-Melanocyte-stimulating hormone
(β-MSH), 1106t
Melanoma, PUVA and, 1814
Melarsoprol, 1427–1428
Meloxicam, 965
adverse effects and side effects of,
990
compared to aspirin, 970t
COX isoform selectivity, 962f
dosage and administration of, 970t
pharmacokinetics of, 970t
pharmacology of, 962f
plasma pharmacokinetics of, 962f
therapeutic uses of, 970t, 990
Melperone, potencies at
neurotransmitter receptors,
427t
Melphalan, 1668t–1670t
toxicity of, extramedullary, 1682t
Melphalan, SLC transporters and, 102t
Memantine, pharmacokinetics of,
1860t
Memory, dopamine and, 357
Menaquinone, 872
MENEST (esterified estrogens), 1839t
Ménière’s disease, H 1
-receptor
antagonists for, 923
Meningitis
bacterial, chloramphenicol for, 1528
gentamicin for, 1515
Meningitis (Cont.):
pneumococcal, penicillin for,
1485–1486
Meningococcal infections, penicillin
for, 1486
Menopausal hormone therapy,
1175–1177
Menopause
age at, 1838
definition of, 1838
hormone-replacement therapy for,
1838–1840
signs and symptoms, 1838
MENOSTAR (estradiol), 1839t
Menstrual cycle, neuroendocrine
control of, 1166–1169
Meperidine
absorption, fate, and excretion of,
506
cardiovascular system and, 506
central nervous system and,
503–505
contraindications to, 506
dosage of, 500t
drug interactions with, 506–507
effects on organ systems, 503–505
metabolism of, 128t
pharmacokinetics of, 1860t
smooth muscle and, 506
structure of, 504f
therapeutic uses of, 507
untoward effects of, 506
Mephentermine, 295
structure of, 279t
Mephenytoin, polymorphisms and
response to, 159t
Mephenytoin hydroxylase, 157
Mephobarbital, 470t
polymorphisms and response to, 159t
Mepivacaine, 573
Meprobamate, 476
metabolism of, 128t
Mequinol
for hyperpigmentation, 1830
mechanism of action of, 1830
Mercaptopurine, 1668t–1670t,
1701–1702
metabolism of, 128t, 139
pharmacokinetics of, 1861t
polymorphisms and, 158
polymorphisms and response to,
161t
therapeutic uses of, for
inflammatory bowel disease,
1352t
Mercury, 1864–1867
Mercury antidote, 86t
Mesalamine
chemistry, 1354–1355
for inflammatory bowel disease,
1354–1356
mechanism of action, 1354–1355
pharmacological properties,
1354–1355
Mesenteric ganglia, 173f
Mesoridazine, potencies at
neurotransmitter receptors,
427t
Metabolic effects
of beta-adrenergic receptor
antagonists, 315
of epinephrine, 285–286
of estrogens, 1169–1170
of oral contraceptives, 1187–1188
progestins and, 1182
of thyroid hormones, 1141
Metabolic rickets, 1289
Metabolic syndrome, 877–878, 891
clinical identification of, 891t
Metabolism interaction, 77
Metabolism of drugs, 27
absorption and, 18f
binding and, 18f
cytochrome P450 superfamily and,
127–130
distribution and, 18f
drug development and, 123–124,
142
effectiveness and, 139–142
endoplasmic reticulum in, 126–127,
126f
excretion and, 18f
flavin-containing monooxygenases
in, 125, 125t, 130
hydrolysis reactions in, 128t
hydrolytic enzymes and, 130–131,
131f
induction of, 140–142, 140t, 141f
intestine in, 126
major reactions in, 128t
metabolism interaction, 77
methylation in, 138–139
nasal mucosa in, 126
oxidative reactions in, 128t
phase I, 124–125, 125t, 127–130
phase II, 125, 125t, 131–139
phases of, 124–125
“poor,” 157
safety and, 139–142
sites of, 125–127, 126f
2045
INDEX